- SynbioTech Launches SYNMUE™ Targeting Immunosenescence, to Showcase at Probiota Americas 2026 in Vancouver — Clinical Study Showed Up to 48% Natural Killer Cell Increase with probiotic strain LP281 VANCOUVER, BC, June 5, 2026 /PRNewswire/ -- Synbio Tech Inc.
- (SynbioTech), a global leader in biotechnology solutions, today announced the launch of SYNMUE™, a clinically validated probiotic featuring...
Operational Impact: This capabilities & scale move can alter CRO vendor risk for comparable outsourcing scopes—confirm whether active partners still meet timeline, compliance, and site-level assumptions. Source: PR Newswire pharma category RSS
- Innovent declares Phase 3 success for ADC that attracted huge Takeda deal — Innovent Biologics' ADC candidate has passed a Phase 3 trial in advanced stomach cancer and is under priority review in China, but details of the success are still under wraps.
- The Phase 3 win will ...
Operational Impact: This capabilities & scale move can alter CRO vendor risk for comparable outsourcing scopes—confirm whether active partners still meet timeline, compliance, and site-level assumptions. Source: Endpoints News RSS
- Zifo Transforms EHS Policy Management with New AI-Enabled Services Accelerator — AI-powered EHS Compliance services accelerator is purpose-designed for pharma, biotech, and medical device companies CAMBRIDGE, Mass.
- and CAMBRIDGE, England, June 5, 2026 /PRNewswire/ -- Zifo, a leading global enabler of AI and data-driven enterprise informatics for science-driven...
Operational Impact: This compliance & quality move can alter CRO vendor risk for comparable outsourcing scopes—confirm whether active partners still meet timeline, compliance, and site-level assumptions. Source: PR Newswire pharma category RSS
- VetrixBio Announces Positive Clinical Data for VTX-304, a First-in-Class Bispecific Antibody for Canine Osteoarthritis — BEVERLY, Mass., June 5, 2026 /PRNewswire/ -- Today at the 6th International Veterinary Pain Short Course hosted at NC State College of Veterinary Medicine, VetrixBio (www.vetrixbio.com) presented the first clinical data for VTX-304, its investigational bispecific antibody designed to...
- VetrixBio Announces Positive Clinical Data for VTX-304, a First-in-Class Bispecific Antibody for Canine Osteoarthritis — outsourcing teams should verify scope against the primary source.
Operational Impact: This capabilities & scale move can alter CRO vendor risk for comparable outsourcing scopes—confirm whether active partners still meet timeline, compliance, and site-level assumptions. Source: PR Newswire pharma category RSS
- Grifols Supports AlphaDetect to Accelerate Detection of Alpha-1 — The sponsorship will help expand proven strategies to consistently detect a genetic, irreversible, and progressive condition in patients with liver and/or lung disease.
- DURHAM, N.C., June 5, 2026 /PRNewswire/ -- AlphaDetect, the nonprofit detection organization powered and funded by the...
Operational Impact: This geographic footprint move can alter CRO vendor risk for comparable outsourcing scopes—confirm whether active partners still meet timeline, compliance, and site-level assumptions. Source: PR Newswire pharma category RSS
How this was written: Transparency methodology
> Some claims require additional source verification.